RecruitingPhase 4NCT06296836
Effect of Continuing Versus Holding Metformin During Hospitalizations.
Effect of Continuing Versus Holding Metformin During Hospitalizations to Internal Medicine on Glucose Control, Acidosis, Abdominal Symptoms, Length of Stay, and Mortality.
Sponsor
University of Illinois at Chicago
Enrollment
300 participants
Start Date
Jan 21, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A randomized study of continuing versus holding metformin during hospitalizations to internal medicine services to determine the effects on glucose control, acidosis, abdominal symptoms, length of stay, and mortality.
Eligibility
Min Age: 18 YearsMax Age: 110 Years
Inclusion Criteria3
- Adult (18+ years of age)
- Admitted to an internal medicine service.
- On Metformin prior to admission.
Exclusion Criteria9
- Inability to take oral medications
- eGFR \< 30 ml/min/1.73 m2
- Dialysis
- Current Acidosis (pH \< 7.35) including diabetic ketoacidosis
- Child-Turcotte-Pugh class C hepatic cirrhosis
- Acute Decompensated Heart Failure
- Cognitively impaired and/or unable to consent
- Lack of or unwillingness to share contact information
- Pregnant women
Interventions
DRUGMetformin
Continuation of home metformin
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06296836
Related Trials
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418115 locations
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
Project Dulce for Arab Americans With Type 2 Diabetes
NCT055805362 locations
Improving Health Outcomes With Kefir
NCT066952211 location
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
NCT038787061 location